Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 In Patients With Solid Tumors Likely to Express NaPi2b
Mersana Therapeutics, in collaboration with IQVIA Biotech
This is a dose escalation and expansion trial, consisting of two parallel cohorts of patients (high grade serous ovarian cancer and non-small cell lung cancer). In the dose escalation part of the trial, increasing doses of XMT-1592 will be administered to groups of patients over time, until the maximum tolerated dose is achieved. In the dose expansion (confirmation) part of the trial, new groups of patients will receive XMT-1592 at the maximum tolerated dose to confirm the recommended Phase 2 dose. XMT-1592 will be administered once every 21 days.